Institute of Hematology, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Tel Aviv University, Israel.
Acta Haematol. 2011;125(1-2):23-31. doi: 10.1159/000318883. Epub 2010 Dec 8.
The course of follicular lymphoma has changed considerably with the introduction of immunotherapy. Systematic reviews and meta-analyses are reliable, efficient and well-established methods to summarize the vast amount of data acquired in recent years on the role of immunotherapy, including monoclonal antibodies, radio-labeled monoclonal antibodies and interferon-α in the treatment of patients with follicular lymphoma. We aimed to summarize the data from systematic reviews assessing immunotherapy for these patients. A search through Medline and the Cochrane Library for systematic reviews of randomized controlled trials of different types of immunotherapy for patients with follicular lymphoma yielded 17 reviews. Eleven of them were eligible for this review and are described herein. These systematic reviews have dramatically influenced the approach to patients with follicular lymphoma.
随着免疫疗法的引入，滤泡性淋巴瘤的病程发生了重大变化。系统评价和荟萃分析是可靠、高效且成熟的方法，可总结近年来获得的大量数据，这些数据涉及免疫疗法在滤泡性淋巴瘤患者治疗中的作用，包括单克隆抗体、放射性标记的单克隆抗体和干扰素-α。我们旨在总结评估这些患者免疫治疗的系统评价数据。通过 Medline 和 Cochrane Library 搜索针对滤泡性淋巴瘤患者不同类型免疫疗法的随机对照试验的系统评价，共获得 17 项综述。其中 11 项符合本综述的纳入标准，并在此处进行描述。这些系统评价极大地影响了滤泡性淋巴瘤患者的治疗方法。
